335 related articles for article (PubMed ID: 18549892)
21. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of Pheochromocytoma of the Adrenal Gland Scaled Score (Pass score) tests to separate benign from malignant neoplasms.
Mlika M; Kourda N; Zorgati MM; Bahri S; Ben Ammar S; Zermani R
Tunis Med; 2013 Mar; 91(3):209-15. PubMed ID: 23588637
[TBL] [Abstract][Full Text] [Related]
23. Pheochromocytoma in Dogs Undergoing Adrenalectomy.
Zini E; Nolli S; Ferri F; Massari F; Gerardi G; Nicoli S; Romanelli G; Montinaro V; Trez D; Cavicchioli L; Ferro S
Vet Pathol; 2019 May; 56(3):358-368. PubMed ID: 30595108
[TBL] [Abstract][Full Text] [Related]
24. Pheochromocytomas: can malignant potential be predicted?
John H; Ziegler WH; Hauri D; Jaeger P
Urology; 1999 Apr; 53(4):679-83. PubMed ID: 10197840
[TBL] [Abstract][Full Text] [Related]
25. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
[TBL] [Abstract][Full Text] [Related]
26. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.
Stenman A; Svahn F; Hojjat-Farsangi M; Zedenius J; Söderkvist P; Gimm O; Larsson C; Juhlin CC
Am J Surg Pathol; 2019 Mar; 43(3):409-421. PubMed ID: 30451732
[TBL] [Abstract][Full Text] [Related]
27. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
Parasiliti-Caprino M; Lucatello B; Lopez C; Burrello J; Maletta F; Mistrangelo M; Migliore E; Tassone F; La Grotta A; Pia A; Reimondo G; Giordano R; Giraudo G; Piovesan A; Ciccone G; Deandreis D; Limone P; Orlandi F; Borretta G; Volante M; Mulatero P; Papotti M; Aimaretti G; Terzolo M; Morino M; Pasini B; Veglio F; Ghigo E; Arvat E; Maccario M
Hypertens Res; 2020 Jun; 43(6):500-510. PubMed ID: 31586159
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
Tavangar SM; Shojaee A; Moradi Tabriz H; Haghpanah V; Larijani B; Heshmat R; Lashkari A; Azimi S
Pathol Res Pract; 2010 May; 206(5):305-9. PubMed ID: 20189725
[TBL] [Abstract][Full Text] [Related]
29. Lack of correlations among histopathological parameters, Ki-67 proliferation index and prognosis in pheochromocytoma patients.
Ocal I; Avci A; Cakalagaoglu F; Can H
Asian Pac J Cancer Prev; 2014; 15(4):1751-5. PubMed ID: 24641403
[TBL] [Abstract][Full Text] [Related]
30. Elevated levels of telomerase activity in malignant pheochromocytoma.
Kubota Y; Nakada T; Sasagawa I; Yanai H; Itoh K
Cancer; 1998 Jan; 82(1):176-9. PubMed ID: 9428495
[TBL] [Abstract][Full Text] [Related]
31. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.
Helman LJ; Cohen PS; Averbuch SD; Cooper MJ; Keiser HR; Israel MA
J Clin Oncol; 1989 Nov; 7(11):1720-5. PubMed ID: 2809684
[TBL] [Abstract][Full Text] [Related]
32. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
Meyer-Rochow GY; Jackson NE; Conaglen JV; Whittle DE; Kunnimalaiyaan M; Chen H; Westin G; Sandgren J; Stålberg P; Khanafshar E; Shibru D; Duh QY; Clark OH; Kebebew E; Gill AJ; Clifton-Bligh R; Robinson BG; Benn DE; Sidhu SB
Endocr Relat Cancer; 2010 Sep; 17(3):835-46. PubMed ID: 20621999
[TBL] [Abstract][Full Text] [Related]
34. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.
Thouënnon E; Elkahloun AG; Guillemot J; Gimenez-Roqueplo AP; Bertherat J; Pierre A; Ghzili H; Grumolato L; Muresan M; Klein M; Lefebvre H; Ouafik L; Vaudry H; Plouin PF; Yon L; Anouar Y
J Clin Endocrinol Metab; 2007 Dec; 92(12):4865-72. PubMed ID: 17878247
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience over 48 years with pheochromocytoma.
Goldstein RE; O'Neill JA; Holcomb GW; Morgan WM; Neblett WW; Oates JA; Brown N; Nadeau J; Smith B; Page DL; Abumrad NN; Scott HW
Ann Surg; 1999 Jun; 229(6):755-64; discussion 764-6. PubMed ID: 10363888
[TBL] [Abstract][Full Text] [Related]
36. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas.
August C; August K; Schroeder S; Bahn H; Hinze R; Baba HA; Kersting C; Buerger H
Mod Pathol; 2004 Sep; 17(9):1119-28. PubMed ID: 15167935
[TBL] [Abstract][Full Text] [Related]
37. Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas.
Petri BJ; Speel EJ; Korpershoek E; Claessen SM; van Nederveen FH; Giesen V; Dannenberg H; van der Harst E; Dinjens WN; de Krijger RR
Mod Pathol; 2008 Apr; 21(4):407-13. PubMed ID: 18223555
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylated histone H3, Ki-67, p21, fatty acid synthase, and cleaved caspase-3 expression in benign and atypical granular cell tumors.
Kapur P; Rakheja D; Balani JP; Roy LC; Amirkhan RH; Hoang MP
Arch Pathol Lab Med; 2007 Jan; 131(1):57-64. PubMed ID: 17227124
[TBL] [Abstract][Full Text] [Related]
39. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
Stenman A; Zedenius J; Juhlin CC
Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
[TBL] [Abstract][Full Text] [Related]
40. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
